Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi

Eur Urol. 1991;20(3):243-7. doi: 10.1159/000471707.

Abstract

In a prospective, double-blind, placebo-controlled study, the efficacy and safety of acetohydroxamic acid (AHA) in preventing urinary calculogenesis was evaluated in 94 patients with chronic urinary infection. Stone growth occurred in 17% of the AHA group and in 46% of the placebo group (p less than 0.005). Completely reversible side effects consisting predominantly of psychoneurologic and musculo-integumentary symptoms were more prevalent in the AHA group (p less than 0.01). Side effects which were judged 'intolerable' were experienced by 10 (22.2%) of patients in the AHA group and 2 (4.1%) in the placebo group. It is concluded that AHA treatment is effective, relatively safe, and clinically useful in preventing infection-induced urinary calculogenesis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Bacteriuria / complications*
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Humans
  • Hydroxamic Acids / therapeutic use
  • Magnesium
  • Magnesium Compounds*
  • Male
  • Middle Aged
  • Palliative Care
  • Phosphates
  • Placebos
  • Prospective Studies
  • Struvite
  • Urinary Calculi / drug therapy*
  • Urinary Calculi / etiology
  • Urinary Calculi / prevention & control

Substances

  • Hydroxamic Acids
  • Magnesium Compounds
  • Phosphates
  • Placebos
  • acetohydroxamic acid
  • Struvite
  • Magnesium